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Pediatric Acute Lymphoblastic Leukemia: Update of
the 2005 Evidence-Based ReviewAmong the primary objectives of the American So-
ciety for Blood and Marrow Transplantation
(ASBMT) are to:
- Define commonly accepted medical and evidence-
based practice.
- Develop standards of medical care for autologous
and allogeneic transplantations.
- Provide recommendations for physicians, patients,
and third-party payers on the role of transplanta-
tion as a therapeutic approach.
Toward this end, in 1999, the Society began spon-
soring evidence-based reviews (EBRs) of the scientific
and medical literature to document when blood and
marrow transplantation is indicated in the treatment
of selected diseases.
In 2009, the ASBMT EBR Steering Committee
determined that previously published reviews should
be updated regularly, at approximately 5-year inter-
vals. The pediatric acute lymphoblastic leukemia
(ALL) EBR is the third in the series to be updated.
GOALS
The goals of the EBRs are to:
- Assemble and critically evaluate all valid, peer-
reviewed evidence regarding the role of cytotoxic
therapy with hematopoietic stem cell transplanta-
tion (SCT) related to the disease.
- Provide treatment recommendations based on the
available evidence.
- Identify discrepancies in study design or methodol-
ogy among published studies that may affect the
quality of the evidence.
- Identify areas of needed research.
The goals of the Pediatric ALL EBR update are to:
- Provide a summary of recent clinical evidence.
- Provide timely treatment recommendations.
- Determine if new evidence strengthens or changes
treatment recommendations provided in the origi-
nal Pediatric ALL EBR published in 2006./$36.00
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RECOMMENDATIONS FOR PEDIATRIC ALL
The following updated treatment recommenda-
tions are offered for the role of SCT as treatment for
ALL in children and are based on consensus reached
by an expert panel [1] after a systematic reviewof the lit-
erature [2] published since the 2005 original EBR [3].
Autologous SCT vs Nontransplantation
Therapy for Pediatric ALL in First Morphologic
Complete Remission
 Based on new evidence, autologous SCT is not rec-
ommended in complete remission (CR1), nor is it
usual practice in children.
Allogeneic SCT vs Nontransplantation Therapy
for Pediatric ALL in CR1
 New data have changed the original recommenda-
tion for Ph1 ALL in children. In the original
evidence-based review published in 2005, there was
a clear advantage for allogeneic SCT for Ph1 ALL
in CR1; however, this was based on data before the
availability of tyrosine kinase inhibitors. New but
preliminary data presented in one small study in
this update, show that early outcomes are comparable
between allogeneic SCT and intensive chemother-
apy with imatinib. Further study is needed to deter-
mine whether imatinib and intensive chemotherapy
should replace allogeneic SCT for some or all Ph1
ALL pediatric patients. Moreover, the role of long-
term use of tyrosine kinase inhibitors is not known.
This is an evolving field in need of further study.
 New data provide a new treatment recommendation
for pediatric patients with T-lineage ALL (T-ALL).
Although there are limited data to make a recom-
mendation, based on expert opinion, allogeneic
SCT may be considered for patients with T-ALL
in CR1. One study showed a benefit for allogeneic
SCT in a subset of patients with T-ALL in CR1;
however, this did not consider modern chemother-
apy results with better event-free survival. There
are subsets of T-ALL that seem to have a worse
prognosis with chemotherapy, but it is not yet979
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tients. This area requires further study.
 New data provide a new treatment recommendation
for pediatric patients with mixed-lineage leukemia
(MLL)1 ALL. Current data do not support alloge-
neic SCT when MLL1 ALL is the sole adverse risk
factor. The presence of MLL1 along with other ad-
verse risk factors (older age, high WBC, prednisone
response, or other cytogenetic abnormalities) has
been used to define very high-risk subgroups for
which allogeneic SCT may be recommended.
 A new treatment recommendation for pediatric pa-
tients with hypodiploid ALL (\44 chromosomes)
is based on expert opinion. Outcomes remain dismal
for hypodiploid ALL treated with modern chemo-
therapy only. Although there are no published data
to make a recommendation, based on expert opin-
ion, allogeneic SCT may be considered. This area
requires further study.
Allogeneic SCT vs Nontransplantation Therapy
for ALL in CR1 after Primary Induction Failure
 New data have changed the original recommenda-
tion for ALL in children who failed to achieve
a CR1 after the first 4 to 6 weeks of initial che-
motherapy (primary induction failure) but who
subsequently achieve a CR1. Allogeneic SCT is
recommended for pediatric patients with ALL who
experience primary induction failure but sub-
sequently achieve a CR1.
Allogeneic SCT vs Nontransplantation Therapy
for ALLwith PersistentMinimal Residual Disease
Positivity in CR1 or Second Complete Remission
 A new treatment recommendation for pediatric
patients with persistent minimal disease (MRD) 1
ALL in CR1 or second complete remission (CR2)
is based on expert opinion. Allogeneic SCT may
be considered for patients who have been identified
by a validated assay as very high risk due to detection
of persistent MRD; however, this is an evolving field
in need of further study.
Allogeneic SCT vs Nontransplantation Therapy
for ALL in CR2
 New data have changed the original recommendation
for pediatric precursor-B ALL in CR2 after
experiencing an early marrow relapse during or within
6 months of therapy completion or\36 months from
diagnosis. Due to a significant survival benefit, alloge-
neic SCT is recommended for patientswith precursor-
B ALL in CR2 after an early marrow relapse.
 New data have changed the original recommendation
for pediatric patientswithprecursor-BALL inCR2af-
ter experiencing a later marrow relapse. There may bea small advantage in event-free survival for allogeneic
SCT, but taking into account salvage therapy, the out-
comes with chemotherapy and allogeneic SCT are
equivalent for late marrow relapses. The decision to
use allogeneic SCT in these patients should be made
by the patient, family, and transplantation team with
consideration of the risks and benefits involved.
 There is a new recommendation for pediatric
patients with T-lineage ALL in CR2 based on
evidence from the original evidence-based review.
Based on one small study and expert opinion, alloge-
neic SCT is recommended for T-ALL in CR2 after
a marrow relapse, however, further study is needed.
 New data provide a new treatment recommendation
for pediatric patients with ALL who are in CR2 after
experiencing an isolated central nervous system
(CNS) relapse. Allogeneic SCT is not recommended
for isolated CNS relapse in patients with precursor-B
ALL because survival of these patients treated with
chemotherapy and radiation therapy is equivalent.
Thereare insufficientdata tomakea recommendation
regarding allogeneic SCT for treatment of an isolated
CNS relapse in pediatric patients with T-ALL.
 There are no data to make a recommendation for or
against allogeneic SCT for treatment of an isolated
testicular relapse.
Allogeneic SCTvsNon-TransplantationTherapy
forALL inThirdorGreaterCompleteRemission
 New data provide a new treatment recommendation
for pediatric patients with ALL who are in third or
greater complete remission ($CR3). Although pedi-
atric patientswithALL in$CR3have a poor progno-
sis regardless of treatment, allogeneic SCT is
recommendedbecause it improves survival outcomes.
Allogeneic SCT vs Nontransplantation Therapy
for ALL Not in Morphologic CR
 A new treatment recommendation for pediatric
patients with ALL who are not in morphologic CR is
based on expert opinion. There are no data to recom-
mendallogeneicSCTforpatients in active relapsewith
measurable disease. Allogeneic SCT for pediatric pa-
tients with ALL with measurable disease produces
long-term disease-free survivals\10%. The decision
to use allogeneic SCT in these patients should be
made by the patient, family, and transplantation team
with consideration of the risks and benefits involved.
Autologous vs Allogeneic SCT
 New data provide a new treatment recommendation
regarding use of an autologous or allogeneic SCT to
treat pediatric patients with ALL. There are no data
to support a benefit for autologous SCT in children.
Autologous SCT is not a recommended treatment,
nor is it standard practice.
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 New data provide a new treatment recommendation
for pediatric patients with ALL treated with an allo-
geneic SCT. Survival outcomes after HLA-matched
related or unrelated donor (URD) allogeneic SCT
are similar. Based on studies in ALL and acute
myeloid leukemia (AML) in the absence of an
HLA-matched related donor, an HLA-matched
URD allogeneic SCT (using marrow, peripheral,
or cord blood) is an acceptable alternative.
Maternal vs Paternal Donor Allogeneic SCT
 There is no recommendation: The new data are in-
sufficient to make a treatment recommendation re-
garding the use of a maternal vs a paternal donor
for allogeneic SCT in pediatric patients with ALL.
HLA-Matched vs HLA-Mismatched URD
Allogeneic SCT
 New data provide a new treatment recommendation
for pediatric patients with ALL treated with an allo-
geneic SCT from an URD. Allogeneic SCT using
the best possible HLA-matched donor is recom-
mended. Although HLA-mismatched URD alloge-
neic SCT may result in higher morbidity and
mortality than HLA-matched URD allogeneic
SCT, this does not preclude performing an HLA-
mismatched URD allogeneic SCT.
Imatinib vs No Imatinib Preallogeneic and/or
Postallogeneic SCT for Ph1 ALL
 There is no recommendation: The new data are
insufficient to make a treatment recommendation
regarding the use of imatinib therapy along with
allogeneic SCT in pediatric patients with Ph1ALL.
Comparison of Conditioning Regimens before
Allogeneic SCT
 New data strengthen the original recommendation
that myeloablative total body irradiation-containing
regimens have better survival outcomes than mye-
loablative regimens without total body irradiation.AREAS OF NEEDED RESEARCH
After reviewing the updated evidence, the expert
panel identified the following important areas of
needed research in pediatric ALL:
1. Re-evaluate allogeneicSCTvs intensive chemother-
apy regimens in the current era, as both approaches
have changed. Comparative studies should be per-
formed using methodology that avoids bias.
2. Investigate the role and potential benefit of mater-
nal antigen microchimerism to reduce the risk ofgraft-versus-host disease and enhance the graft-
versus-leukemia effect after allogeneic bone mar-
row transplantation.
3. Identify and address the treatment of high-risk
T-ALL subsets.
4. Reevaluate the promising early studies of imatinib
in combination with chemotherapy or SCT for
Ph1 ALL in larger studies.
5. Investigate the optimal treatment for patients who
are persistently positive forminimal residual disease.
6. Improve the detection and monitoring of MRD
during initial treatment to guide individual patient
eligibility and timing of allogeneic SCT.
7. Monitoring MRD after SCT to detect early post-
SCT relapse in need of preemptive therapy.
8. Investigate the indications for using reduced
intensity vs myeloablative-conditioning regimens
for allogeneic SCT.
9. Determine conditioning regimens that reduce or
eliminate the need for total body irradiation while
maintaining effectiveness for ALL.
10. Investigate the prognostic role of initial risk classi-
fication (NCI standard vs high risk assignment) on
outcomes after relapse.
11. Investigate whether allogeneic SCT performed in
CR1 patients identified as very high risk for re-
lapse by molecular methods (ie, specific gene
mutations, gene expression profiles, etc.) improves
outcome compared to chemotherapy.
12. Investigate the impact of psychosocial support and
shared decision-making models to assist families
in weighing the risks vs benefits of SCT for their
children with ALL.
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